Ruth Kelly

Dr. Ruth Kelly

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RKRuth Kelly
Ruth Kelly
KPKristin M. Perkumas
Kristin M. Perkumas
MCMatthew Campbell
Matthew Campbell
GFG. Jane Farrar
G. Jane Farrar
WSW. Daniel Stamer
W. Daniel Stamer
COColm O'Brien
Colm O'Brien
Previous studies have shown that glaucomatous Schlemm’s canal endothelial cells (gSCECs) are stiffer and associated with reduced porosity and increased extracellular matrix (ECM) material compared to SCECs from healthy individuals. We hypothesised that Schlemm’s canal (SC) cell stiffening was a function of fibrotic changes occurring at the inner wall of SC in glaucoma. This study was performed in primary cell cultures isolated from the SC lumen of human donor eyes. RNA and protein quantification of both fibrotic and endothelial cell markers was carried out on both healthy and gSCECs. Functional assays to assess cell density, size, migration, proliferation, and mitochondrial function of these cells were also carried out. Indeed, we found that gSCECs deviate from typical endothelial cell characteristics and exhibit a more fibrotic phenotype. For example, gSCECs expressed significantly higher protein levels of the fibrotic markers α-SMA, collagen I-α1, and fibronectin, as well as significantly increased protein expression of TGFβ-2, the main driver of fibrosis, compared to healthy SCECs. Interestingly, we observed a significant increase in protein expression of endothelial marker VE-cadherin in gSCECs, compared to healthy SCECs. gSCECs also appeared to be significantly larger, and surprisingly proliferate and migrate at a significantly higher rate, as well as showing significantly reduced mitochondrial activity, compared to healthy SCECs.

1 March 2021 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
PCPaul S. Cassidy
Paul S. Cassidy
RKRuth Kelly
Ruth Kelly
EREster Reina-Torres
Ester Reina-Torres
JSJoseph M. Sherwood
Joseph M. Sherwood
MHMarian M. Humphries
Marian M. Humphries
JOJeffrey O’cAllaghan
Jeffrey O’cAllaghan
Systemic or localized application of glucocorticoids (GCs) can lead to iatrogenic ocular hypertension, which is a leading cause of secondary open-angle glaucoma and visual impairment. Previous work has shown that dexamethasone increases zonula occludens-1 (ZO-1) protein expression in trabecular meshwork (TM) cells, and that an antisense oligonucleotide inhibitor of ZO-1 can abolish the dexamethasone-induced increase in trans-endothelial flow resistance in cultured Schlemm’s canal (SC) endothelial and TM cells. We have previously shown that intracameral inoculation of small interfering RNA (siRNA) targeting SC endothelial cell tight junction components, ZO-1 and tricellulin, increases aqueous humor outflow facility ex vivo in normotensive mice by reversibly opening SC endothelial paracellular pores. In this study, we show that targeted siRNA downregulation of these SC endothelial tight junctions reduces intraocular pressure (IOP) in vivo, with a concomitant increase in conventional outflow facility in a well-characterized chronic steroid-induced mouse model of ocular hypertension, thus representing a potential focused clinical application for this therapy in a sight-threatening scenario.

20 October 2014 in ISEE Conference Abstracts
Verified
Journal Article
Closed access
IBIoannis Bakolis
Ioannis Bakolis
NBNicky Best
Nicky Best
DFDaniela Fecht
Daniela Fecht
AHAnna L. Hansell
Anna L. Hansell
CMChristopher Millett
Christopher Millett
SHSusan Hodgson
Susan Hodgson
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.